Journal of International Oncology

Journal of International Oncology ›› 2019, Vol. 46 ›› Issue (10): 631-633.doi: 10.3760/cma.j.issn.1673-422X.2019.10.014

Previous Articles     Next Articles

New progress of cabozantinib in the treatment of metastatic renal cell carcinoma

Mei Yanxia1, Zhao Yizhou2   

  1. 1Department of Science and Education, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310000, China; 2Department of Science and Education, First Affilicated Hospital, Zhejiang University School of Medicine, Hangzhou 310000, China

  • Online:2019-10-08 Published:2019-12-22
  • Contact: Mei Yanxia, Email: meiyanxia.123@163.com E-mail:meiyanxia.123@163.com

PDF

261

Abstract:

Renal cell carcinoma (RCC), the most common form of kidney cancer, is characteristic by difficult in diagnosis at an early stage, insensitivity to chemoradiotherapy, poor prognosis, etc.. Localized RCC is treated by surgery while advanced RCC is mainly treated by immunotherapy and targeted therapy. With the ongoing in-depth researches on targeted therapy in recent years, plenty of targeted drugs come into the market in succession. Cabozantinib has been approved for the treatment of advanced RCC in the first/second line setting. It′s safety profile and efficiency have been demonstrated in Ⅱ-Ⅲ clinical trials.

Key words:

Carcinoma, renal cell, Clinical trial, Cabozantinib ,